Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3767-3776

  Amstutz, Ralf ^a   Wachtel, Marco ^a   Troxler, Heinz ^a   Kleinert, Peter ^a   Ebauer, Margret ^a   Haneke, Torsten ^a   Oehler Jänne, Christoph ^b   Fabbro, Doriano ^c   Niggli, Felix K ^a   Schäfer, Beat W ^a,d  

^a University Children's Hospital   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CASPASE 3; CGP 59326; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MIDOSTAURIN; NVP ABG424 NX 4; PLACEBO; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; FOXO1 PROTEIN, MOUSE; PAIRED BOX TRANSCRIPTION FACTOR; PAX3 PROTEIN, HUMAN; PAX3 PROTEIN, MOUSE; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA BINDING; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; RNA PROCESSING;

ANIMALS; ANTINEOPLASTIC AGENTS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PAIRED BOX TRANSCRIPTION FACTORS; PHOSPHORYLATION; RHABDOMYOSARCOMA; RNA PROCESSING, POST-TRANSCRIPTIONAL; STAUROSPORINE;

EID: 45549098078     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2447     Document Type: Article

References (35)

1. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
2. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 2006;18:578-83.
3. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
4. Merlino G, Helman LJ. Rhabdomyosarcoma - working out the pathways. Oncogene 1999;18:5340-8.
5. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2002;20:2672-9.
6. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20.
7. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ III, Schafer BW. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 1996;93:13164-9.
8. Ebauer M, Wachtel M, Niggli FK, Schäfer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2β as a mediator of the survival function of PAX3/FKHR. Oncogene 2007;26:7267-81.
9. Ayyanathan K, Fredericks WJ, Berking C, et al. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 2000;60:5803-14.
10. Fabbro D, Ruetz S, Bodis S, et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
11. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
12. Scholl FA, Betts DR, Niggli FK, Schafer BW. Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression. Br J Cancer 2000;82:1239-45.
13. Wachtel M, Frei K, Ehler E, Fontana A, Winterhalter K, Gloor SM. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci 1999;112:4347-56.
14. Gorg A, Obermaier C, Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000;21:1037-53.
15. Czerny T, Schaffner G, Busslinger M. DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev 1993;7:2048-61.
16. Xia SJ, Barr FG. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene 2004;23:6864-71.
17. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004;116:551-63.
18. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-45.
19. Hosoi H, Dilling MB, Shikata T, et al. Rapamycincauses poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94.
20. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005;24:1860-72.
21. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19:1485-92.
22. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
23. Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.
24. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004;101:14479-84.
25. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005;24:8259-67.
26. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006;107:752-9.
27. Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma 2005;46:899-908.
28. Cai Y, Lechner MS, Nihalani D, Prindle MJ, Holzman LB, Dressler GR. Phosphorylation of Pax2 by the c-Jun N-terminal kinase and enhanced Pax2-dependent transcription activation. J Biol Chem 2002;277:1217-22.
29. Mikkola I, Bruun JA, Bjorkoy G, Holm T, Johansen T. Phosphorylation of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. J Biol Chem 1999;274:15115-26.
30. Van Renterghem P, Vassart G, Christophe D. Pax 8 expression in primary cultured dog thyrocyte is increased by cyclic AMP. Biochim Biophys Acta 1996;1307:97-103.
31. Brunelli S, Relaix F, Baesso S, Buckingham M, Cossu G. β Catenin-independent activation of MyoD in presomitic mesoderm requires PKC and depends on Pax3 transcriptional activity. Dev Biol 2007;304:604-14.
32. Fortin AS, Underhill DA, Gros P. Helix 2 of the paired domain plays a key role in the regulation of DNAbinding by the Pax-3 homeodomain. Nucleic Acids Res 1998;26:4574-81.
33. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006;33:407-20.
34. Karamouzis MV, Gorgoulis VG, Papavassiliou AG. Transcription factors and neoplasia: vistas in novel drug design. Clin Cancer Res 2002;8:949-61.
35. Gardner KH, Montminy M. Can you hear me now? Regulating transcriptional activators by phosphorylation. Sci STKE 2005;2005:pe44.